Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biopharmaceutical company Actelion has reported a net income of CHF321.5 million, or CHF2.60 per diluted share, for the full year 2008, an increase of 158%, compared to CHF124.6 million, or CHF1 per diluted share, for the full year 2007.
Subscribe to our email newsletter
For the full year 2008, the company posted net revenues of CHF1.47 billion, an increase of 12%, compared to CHF1.32 billion for the full year 2007.
Jean-Paul Clozel, CEO of Actelion, said: “In 2008, Actelion has executed successfully in all important areas. Despite increasing competition, our products continue to grow. Our preclinical and clinical efforts have resulted in a broad pipeline, with 10 compounds currently investigated in humans.
“Together with the strengthening of our global infrastructure and recruitment of some of the best talent in the industry, Actelion is prepared to continue its growth path in 2009. I expect product sales to grow and I expect more compounds to enter into man this year. With two out of the four Phase III programs reporting final results this year, 2009 has the potential to not only be a year of growth, but also one of transformation for Actelion.”